Tag - Zylö Therapeutics

Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program

Antonette Ho2023-06-04T19:05:34-04:00Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $294,000 Small Business Technology Transfer Research (STTR) grant to: (i) demonstrate that a formulation of N-acylethanolamine (AEA or anandamide) loaded into Zylö’s novel Z-pod delivery system is efficacious (and well tolerated) in a new mouse model of cutaneous lupus developed at Yale University, and (ii) conduct preliminary stability studies to prepare for an eventual investigational new drug (IND) application to the FDA. Read more >>

SCBIO caps annual conference in Charleston with $5,000 pitch competition

Antonette Ho2023-03-06T00:25:07-05:00To close out the SCBIO 2023 conference, three South Carolina early startups in the life sciences industry pitched venture capitalists in a “Rapid Fire: SC Super Pitch” competition in the ballroom of the Gaillard Center with hundreds of attendees in the crowd. Each company had an eight-minute pitch and then two minutes for questions and answers. Three venture capitalists — who had just spoken on a panel about how to give a good pitch — determined the winner, who was...

VentureSouth invested $12M in 34 companies in 2022

Antonette Ho2023-02-14T19:48:34-05:00VentureSouth, one of the Top 10 angel investment groups in North America, provided $12 million in capital investment to 34 companies in 2022, the organization announced Jan. 17. VentureSouth also made additional investments in nearly two dozen existing portfolio companies, including: Zylo Therapeutics. n November 2022, the organization announced it planned to partner with the investor group 757 Angels. The partnership, which will bring 757 Angels into VentureSouth’s network in June, is the angel investment group’s second market in Virginia...

Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED

Ziad2022-11-25T13:59:44-05:00Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases,...

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)

Ziad2022-11-25T13:59:44-05:00Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $600,000 Small Business Innovation Research (SBIR) grant to generate a final formulation of Zylö’s proprietary nitric oxide-releasing topical drug candidate optimized for the treatment of onychomycosis. The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH. Read more >>

Nine Upstate organizations named as 2022 InnoVision Awards finalists

Ziad2022-11-25T13:59:45-05:00Nine Upstate organizations were named as 2022 InnoVision Awards finalists, the organization’s board of directors announced Aug. 2. The awards honor South Carolina individuals and organizations for impactful innovations under development in the state within the last 18 months. Awards will be given in six categories. One of The nominees: Technology Integration-Zylo Therapeutics Inc. – Greenville. All finalists will be recognized during the virtual InnoVision 2022 Meet the Finalists Series sponsored by South Carolina Research Authority. Read more >>

Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Ziad2022-11-25T13:59:45-05:00Silo Pharma, Inc., a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in...

Zylö Therapeutics Closes $5.225 Million Series B Financing

Ziad2022-11-25T13:59:45-05:00Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium of seasoned investors, spearheaded by James Cordes, who recently joined the Zylö board of directors. Other key participants were: (i) VentureSouth (which led the Series A round) which invested more than $1.3 million in the Series B round; (ii) the New York Angels, an angel group that has played...

Startup: Zylö Therapeutics — Small company, big idea

Ziad2022-11-25T13:59:58-05:00Scott Pancoast believes he can put Greenville on the map with his company’s product, and he’s ready to take it to the world. Zylö Therapeutics is a technology startup that uses a silica powder, called Z-pods — very similar in consistency to talcum powder — to be the vehicle of transport for everything from pain relievers to pesticides. The Z-pods have far-reaching medical applications, as they’ve shown promise in promoting hair growth, treating acne, relieving pain, helping with erectile dysfunction...

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics

Ziad2022-11-25T14:00:10-05:00Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Read more >>